GSK Wins Strong Shareholder Backing at 26th Annual General Meeting

GlaxoSmithKline ( (GB:GSK) ) has issued an announcement.

GSK reported that all 25 resolutions at its 26th Annual General Meeting, held as a hybrid event in London, were passed by shareholder poll, including the adoption of the 2025 Annual Report, approval of its remuneration report and policy, and the re-election or election of all directors. Shareholders also backed the reappointment and pay of the auditor, authorities to allot shares and buy back stock, adjustments to pre-emption rights, and amended Articles of Association, with voting participation rising to 76.59% of issued share capital, underscoring solid investor support for the company’s governance and capital management framework.

The most recent analyst rating on (GB:GSK) stock is a Hold with a £21.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

Spark’s Take on GSK Stock

According to Spark, TipRanks’ AI Analyst, GSK is a Neutral.

The score is driven primarily by solid underlying financial performance (strong margins and improved earnings) and supportive valuation (low P/E with a ~3.47% yield). These positives are partially offset by weak technical momentum (below key moving averages with negative MACD) and financial risk factors including meaningful leverage and uneven free-cash-flow consistency.

To see Spark’s full report on GSK stock, click here.

More about GlaxoSmithKline

GSK is a global biopharma company focused on uniting science, technology and talent to develop medicines and vaccines that help people get ahead of disease. The group operates worldwide, with a strong presence in major healthcare markets, and targets both prevention and treatment across a broad range of therapeutic areas.

Average Trading Volume: 9,291,947

Technical Sentiment Signal: Buy

Current Market Cap: £75.89B

See more insights into GSK stock on TipRanks’ Stock Analysis page.